Bonesupport Holding AB
STO:BONEX

Watchlist Manager
Bonesupport Holding AB Logo
Bonesupport Holding AB
STO:BONEX
Watchlist
Price: 386.6 SEK 1.2% Market Closed
Market Cap: 25.4B SEK
Have any thoughts about
Bonesupport Holding AB?
Write Note

Bonesupport Holding AB
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bonesupport Holding AB
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Bonesupport Holding AB
STO:BONEX
Revenue
kr814.5m
CAGR 3-Years
58%
CAGR 5-Years
44%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Revenue
kr1.3B
CAGR 3-Years
20%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Revenue
kr3.6B
CAGR 3-Years
32%
CAGR 5-Years
21%
CAGR 10-Years
22%
Probi AB
STO:PROB
Revenue
kr642.7m
CAGR 3-Years
-3%
CAGR 5-Years
0%
CAGR 10-Years
19%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Revenue
kr25.4B
CAGR 3-Years
19%
CAGR 5-Years
16%
CAGR 10-Years
26%
BioArctic AB
STO:BIOA B
Revenue
kr616m
CAGR 3-Years
115%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
No Stocks Found

Bonesupport Holding AB
Glance View

Market Cap
25.8B SEK
Industry
Biotechnology

Bonesupport Holding AB, a Swedish company, has carved a niche for itself in the intricate world of orthopedic treatments and regenerative medicine. Founded in 1999, the company's journey is rooted in innovation and development of injectable bio-ceramic bone graft substitutes, primarily aimed at addressing bone voids and other skeletal maladies. The cornerstone of their business is the proprietary CERAMENT platform, which combines biocompatible, synthetic materials with a unique ability to promote bone healing and integration. By offering solutions that are resorbable and can enhance the regrowth of natural bone, Bonesupport targets clinicians and professionals in orthopedics, trauma, and spine surgery, offering them alternatives to traditional bone grafting methods. The company's products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V, differentiate themselves by also being antibiotic-eluting—allowing for the simultaneous treatment of bone diseases and infection mitigation. Bonesupport's revenue models revolve around both direct sales and leveraging distribution partnerships in key markets, including Europe, the United States, and emerging regions. The company channels substantial investments into research and development, seeking to broaden the clinical applications of their technologies thus driving adoption in the market. They benefit from a growing interest in minimally invasive treatments among healthcare providers, who aim to enhance patient outcomes while also controlling costs. By continuing to expand its product portfolio and advancing clinical evidence, Bonesupport maintains a competitive edge in skeletal health, translating innovation and efficacy into profitability and market growth. This strategic pursuit of advanced bone treatment technologies underscores their role in transforming standard medical practices, ensuring they remain at the forefront of bone health solutions.

BONEX Intrinsic Value
275.4 SEK
Overvaluation 29%
Intrinsic Value
Price

See Also

What is Bonesupport Holding AB's Revenue?
Revenue
814.5m SEK

Based on the financial report for Sep 30, 2024, Bonesupport Holding AB's Revenue amounts to 814.5m SEK.

What is Bonesupport Holding AB's Revenue growth rate?
Revenue CAGR 5Y
44%

Over the last year, the Revenue growth was 56%. The average annual Revenue growth rates for Bonesupport Holding AB have been 58% over the past three years , 44% over the past five years .

Back to Top